News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Acceleron Pharma’s ACE-536 Corrects Anemia and Iron Overload in Preclinical Model of Beta-Thalassemia


10/25/2012 9:54:09 AM

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, presented data today at the 3rd Pan-European Conference on Hemoglobinopathies and Rare Anemias in Limassol, Cyprus, demonstrating positive effects of ACE-536 to treat both the severe anemia and serious organ damage due to iron overload in a preclinical model of beta-thalassemia. Acceleron is developing ACE-536 in collaboration with Celgene.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES